NeuroSCORE is a Genome-wide Omics-based Model That Identifies Candidate Disease Genes of the Central Nervous System

Overview

Journal Sci Rep

Specialty Science

Date 2022 Apr 1

PMID 35361823

Authors

Kyle W Davis

Colleen G Bilancia

Megan Martin

Rena Vanzo

Megan Rimmasch

Yolanda Hom

Mohammed Uddin

Moises A Serrano

Affiliations

Soon will be listed here.

Abstract

To identify candidate disease genes of central nervous system (CNS) phenotypes, we created the Neurogenetic Systematic Correlation of Omics-Related Evidence (NeuroSCORE). We identified five genome-wide metrics highly associated with CNS phenotypes to score 19,601 protein-coding genes. Genes scored one point per metric (range: 0-5), identifying 8298 scored genes (scores ≥ 1) and 1601 "high scoring" genes (scores ≥ 3). Using logistic regression, we determined the odds ratio that genes with a NeuroSCORE from 1 to 5 would be associated with known CNS-related phenotypes compared to genes that scored zero. We tested NeuroSCORE using microarray copy number variants (CNVs) in case-control cohorts and aggregate mouse model data. High scoring genes are associated with CNS phenotypes (OR = 5.5, p < 2E), enriched in case CNVs, and mouse ortholog genes that cause behavioral and nervous system abnormalities. We identified 1058 high scoring genes with no disease association in OMIM. Transforming the logistic regression results indicates high scoring genes have an 84-92% chance of being associated with a CNS phenotype. Top scoring genes include GRIA1, MAP4K4, SF1, TNPO2, and ZSWIM8. Finally, we interrogated CNVs in the Clinical Genome Resource, finding the majority of clinically significant CNVs contain high scoring genes. These findings can direct future research and improve molecular diagnostics.

References

Srivastava S, Love-Nichols J, Dies K, Ledbetter D, Martin C, Chung W . Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019; 21(11):2413-2421. PMC: 6831729. DOI: 10.1038/s41436-019-0554-6. View

Williams S, An J, Edson J, Watts M, Murigneux V, Whitehouse A . An integrative analysis of non-coding regulatory DNA variations associated with autism spectrum disorder. Mol Psychiatry. 2018; 24(11):1707-1719. DOI: 10.1038/s41380-018-0049-x. View

Shukla S, Tekwani B . Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Front Pharmacol. 2020; 11:537. PMC: 7194116. DOI: 10.3389/fphar.2020.00537. View

Pandey A, Lu L, Wang X, Homayouni R, Williams R . Functionally enigmatic genes: a case study of the brain ignorome. PLoS One. 2014; 9(2):e88889. PMC: 3921226. DOI: 10.1371/journal.pone.0088889. View

Iossifov I, ORoak B, Sanders S, Ronemus M, Krumm N, Levy D . The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014; 515(7526):216-21. PMC: 4313871. DOI: 10.1038/nature13908. View

Martin J, Hosking G, Wadon M, Agha S, Langley K, Rees E . A brief report: de novo copy number variants in children with attention deficit hyperactivity disorder. Transl Psychiatry. 2020; 10(1):135. PMC: 7217839. DOI: 10.1038/s41398-020-0821-y. View

van de Willige D, Hoogenraad C, Akhmanova A . Microtubule plus-end tracking proteins in neuronal development. Cell Mol Life Sci. 2016; 73(10):2053-77. PMC: 4834103. DOI: 10.1007/s00018-016-2168-3. View

Bergstrand S, Bohm S, Malmgren H, Norberg A, Sundin M, Nordgren A . Biallelic mutations in WRAP53 result in dysfunctional telomeres, Cajal bodies and DNA repair, thereby causing Hoyeraal-Hreidarsson syndrome. Cell Death Dis. 2020; 11(4):238. PMC: 7165179. DOI: 10.1038/s41419-020-2421-4. View

Limanaqi F, Biagioni F, Gambardella S, Familiari P, Frati A, Fornai F . Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies. Int J Mol Sci. 2020; 21(8). PMC: 7215558. DOI: 10.3390/ijms21083028. View

10.

Coe B, Stessman H, Sulovari A, Geisheker M, Bakken T, Lake A . Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. Nat Genet. 2018; 51(1):106-116. PMC: 6309590. DOI: 10.1038/s41588-018-0288-4. View

11.

Kosmicki J, Samocha K, Howrigan D, Sanders S, Slowikowski K, Lek M . Refining the role of de novo protein-truncating variants in neurodevelopmental disorders by using population reference samples. Nat Genet. 2017; 49(4):504-510. PMC: 5496244. DOI: 10.1038/ng.3789. View

12.

Bult C, Blake J, Smith C, Kadin J, Richardson J . Mouse Genome Database (MGD) 2019. Nucleic Acids Res. 2018; 47(D1):D801-D806. PMC: 6323923. DOI: 10.1093/nar/gky1056. View

13.

Rodriguez J, Pozo F, Di Domenico T, Vazquez J, Tress M . An analysis of tissue-specific alternative splicing at the protein level. PLoS Comput Biol. 2020; 16(10):e1008287. PMC: 7561204. DOI: 10.1371/journal.pcbi.1008287. View

14.

Bagheri H, Badduke C, Qiao Y, Colnaghi R, Abramowicz I, Alcantara D . Identifying candidate genes for 2p15p16.1 microdeletion syndrome using clinical, genomic, and functional analysis. JCI Insight. 2016; 1(3):e85461. PMC: 5033885. DOI: 10.1172/jci.insight.85461. View

15.

Zhao Y, Guo T, Fiksinski A, Breetvelt E, McDonald-McGinn D, Crowley T . Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects. Am J Med Genet A. 2018; 176(10):2172-2181. PMC: 6209529. DOI: 10.1002/ajmg.a.40359. View

16.

Olthof A, Rasmussen J, Campeau P, Kanadia R . Disrupted minor intron splicing is prevalent in Mendelian disorders. Mol Genet Genomic Med. 2020; 8(9):e1374. PMC: 7507305. DOI: 10.1002/mgg3.1374. View

17.

Seidlitz J, Nadig A, Liu S, Bethlehem R, Vertes P, Morgan S . Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disorders. Nat Commun. 2020; 11(1):3358. PMC: 7335069. DOI: 10.1038/s41467-020-17051-5. View

18.

Morris C, Mervis C, Hobart H, Gregg R, Bertrand J, Ensing G . GTF2I hemizygosity implicated in mental retardation in Williams syndrome: genotype-phenotype analysis of five families with deletions in the Williams syndrome region. Am J Med Genet A. 2003; 123A(1):45-59. DOI: 10.1002/ajmg.a.20496. View

19.

Guillen Sacoto M, Tchasovnikarova I, Torti E, Forster C, Andrew E, Anselm I . De Novo Variants in the ATPase Module of MORC2 Cause a Neurodevelopmental Disorder with Growth Retardation and Variable Craniofacial Dysmorphism. Am J Hum Genet. 2020; 107(2):352-363. PMC: 7413887. DOI: 10.1016/j.ajhg.2020.06.013. View

20.

Sawyer I, Sturgill D, Sung M, Hager G, Dundr M . Cajal body function in genome organization and transcriptome diversity. Bioessays. 2016; 38(12):1197-1208. PMC: 5225948. DOI: 10.1002/bies.201600144. View